Inozyme Pharma Announces Dosing Of First Infant With ENPP1 Deficiency In A Phase 1b Trial Of INZ-701
Portfolio Pulse from Happy Mohamed
Inozyme Pharma has announced the dosing of the first infant in its ENERGY-1 trial, a Phase 1b clinical trial of INZ-701 for treating ENPP1 Deficiency. The trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in infants. The company plans to provide a program update in July 2023.
June 27, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma has initiated the dosing of the first infant in its Phase 1b trial of INZ-701 for ENPP1 Deficiency, with a program update expected in July 2023.
The initiation of the Phase 1b trial for INZ-701 in infants with ENPP1 Deficiency is a significant milestone for Inozyme Pharma. Positive results from the trial could potentially lead to a new treatment option for this rare disease, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100